PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

PHASE2CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

April 5, 2019

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Breast CancerAdvanced Breast CancerHormone Receptor Positive TumorHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions
DRUG

Palbociclib

Palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks

DRUG

Endocrine therapy

Endocrine therapy alone (letrozole or fulvestrant)

Trial Locations (53)

10003

Hospital San Pedro de Alcantara, Cáceres

15009

Centro Oncológico de Galicia, A Coruña

20141

Instituto Europeo di Oncologia, Milan

28040

Hospital Clinico San Carlos, Madrid

28050

Hospital Universitario Sanchinarro, Madrid

29010

Hospital Regional Universitario de Malaga, Málaga

36312

Hospital Álvaro Cunqueiro, Vigo

41009

Hospital Universitario Virgen de la Macarena, Seville

46009

Instituto Valenciano de Oncología IVO, Valencia

46014

Hospital General Universitari de Valencia, Valencia

48013

Hospital de Basurto, Bilbao

50009

Hospital Lozano Blesa, Zaragoza

67000

Centre Paul Strauss, Strasbourg

85925

CHD Vendee, La Roche-sur-Yon

Unknown

Hôpital Jean Minjoz, Besançon

Polyclinique Bordeaux Nord Aquitaine, Bordeaux

Centre Georges François Leclerc, Dijon

Hopital Europeen Georges Pompidou, Paris

Hôpital Tenon AP-HP, Paris

University Hospital Dresden-GYN, Dresden

Kliniken Essen Mitte, Essen

Universitätsklinikum Essen Frauenklinik, Essen

AGAPLESION Markus Krankenhaus, Frankfurt

Technical University Munich, Munich

UKM Brustzentrum, Münster

Klinikum Ernst von Bergmann, Potsdam

Klinikum Mutterhaus der Borromäerinnen Trier, Trier

Ospedale Civili Brescia, Brescia

Oncologia Medica Ospedale di Prato, Prato

Policlinico Universitario Campus Bio-medico, Roma

Onkološki Inštitut Ljubljana, Ljubljana

Univerzitetni klinicni center Maribor Oddelek za onkologijo, Maribor

ICO Badalona, Badalona

Hospital Provincial de Castellón, Castelló

H. Vall Hebrón, Barcelona

Hospital del Mar, Barcelona

Institut Català d'Oncologia, Girona

Hospital Arnau de Vilanova, Lleida

Hospital La Paz, Madrid

Hospital Sant Joan, Reus

Hospital Universitario Virgen del Rocío, Seville

Hospital Arnau de Vilanova de Valencia, Valencia

Hospital Universitari i Politecnic La Fe, Valencia

Hospital Miguel Servet, Zaragoza

Darent Valley Hospital by Dartford and Gravesham NHS Trust, Dartford

Barts Cancer Institute, London

08191

Consorci Sanitari de Terrassa, Terrassa

08908

Institut Català d'Oncologia Bellvitge, Barcelona

07120

Hospital Universitari Son Espases, Palma de Mallorca

G12 0YN

Beatson West of Scotland Cancer Center, Glasgow

ME16 9QQ

Kent Oncology Department, Maidstone

SA127BR

Abertawe Bro Morgannwg University Local Health Board, Singleton Hospital, Swansea

TR1 3LQ

Royal Cornwall Hospital NHS Trust, Truro

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

MedSIR

OTHER

NCT03809988 - PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) | Biotech Hunter | Biotech Hunter